BioWorld

Oct. 11, 2002

House Members Grill FDA, ImClone On Approval Process

WASHINGTON - The series of missteps surrounding the application process for ImClone Systems Inc.'s cancer drug, Erbitux, has forced the FDA to rethink some of its procedures. (BioWorld Today) Read More

Genentech Meets Expectations, But Analysts Express Caution

Human Genome Reveals Malaria Resistance Gene Variations Over Past 10,000 Years Of Civilization

Northwest Biotherapeutics Cuts Back, Suspends Phase III Trial

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Flow Neuro wins FDA nod for at-home device for depression

BioWorld MedTech

Flow Neuroscience AB received U.S. FDA 510(k) approval for its Flow at-home brain-stimulation device to treat major depressive disorder. The wearable headset uses...